Description:
IC50 Value: N /A
LDK378 is a highly selective inhibitor of an important cancer target, anaplastic lymphoma kinase (ALK) [1].
LDK378 has received Breakthrough Therapy designation by the US Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during treatment with, or were intolerant to, crizotinib.
Approximately 3-8% of patients with NSCLC have the ALK gene mutation [1]. There are limited treatment options for patients with ALK+ NSCLC, who tend to be non-smokers and younger than NSCLC patients without an ALK translocation [2].
in vitro: N/A
in vivo: N/A
Clinical trial: LDK-378 in Adult Patients With ALK-Activated NSCLC Previously Treated With Chemotherapy and Crizotinib . Phase 2